Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBACCA) nested within a compassionate use program

BACKGROUND: Randomized trials have shown a survival benefit for regorafenib over placebo in patients with metastatic colorectal cancer (mCRC) that progressed after standard therapies. We evaluated survival and safety outcomes in patients treated with regorafenib in a real-life setting. METHODS: REBE...

Descripción completa

Detalles Bibliográficos
Autores principales: Adenis, Antoine, de la Fouchardiere, Christelle, Paule, Bernard, Burtin, Pascal, Tougeron, David, Wallet, Jennifer, Dourthe, Louis-Marie, Etienne, Pierre-Luc, Mineur, Laurent, Clisant, Stéphanie, Phelip, Jean-Marc, Kramar, Andrew, Andre, Thierry
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4936193/
https://www.ncbi.nlm.nih.gov/pubmed/27389564
http://dx.doi.org/10.1186/s12885-016-2440-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4936193/
https://www.ncbi.nlm.nih.gov/pubmed/27389564
http://dx.doi.org/10.1186/s12885-016-2440-9

Ejemplares similares